ga naar hoofdinhoud
Vademecum Huidtumoren Melanoom Literatuur en richtlijnen

Literatuur cutaan melanoom

  1. Eggermont et al. Adjuvant pembrolizumab in resected stage III melanoma. N Engl J Med. 2018;  379(6):593-595. Doi: 10.1056/nejmc1807505
  2. Hauschild et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol 2018; Doi: 10.1200/jco.18.01219
  3. Weber J et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017; 377(19) 1824-1835. Doi: 10.1056/nejmoa1709030
  4. Long GV et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med, 2017; 377(19) 1813-1823. Doi: 10.1056/nejmoa1708539
  5. Long GV et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372:320‐330
  6. Schachter J et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open‐label phase 3 study (KEYNOTE‐006). Lancet. 2017; 390:1853‐1862
  7. Wolchok JD et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022; Jan 10; 40(2):127-137
  8. Betof Warner A et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J Clin Oncol. 2020; May 20; 38(15):1655-1663 
  9. Pires da Silva I et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 Jun; 22(6):836-847
  10. Rohaan MW et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 2022; 387:2113-25
  11. Robert C et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019 Aug 15; 381(7):626-636. Doi: 10.1056/NEJMoa1904059
  12. Dummer R et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J Clin Oncol. 2022 Dec 20; 40(36):4178-4188. Doi: 10.1200/JCO.21.02659. Erratum: J Clin Oncol. 2023 Apr 20; 41(12):2301
  13. Patel et al. Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. NEJM 2023; 388:813-823
  14. Blank et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. NEJM 2024, Doi: 10.1056/NEJMoa24026

Literatuur oogmelanoom

  1. Nathan P et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med 2021; 385:1196-1206. Doi: 10.1056/NEJMoa2103485
  2. Pelster MS et al (2021). Nivolumab and ipiliumumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol 2021; 39(6):599-607. Doi: 10.1200/JCO.20.00605

Commissie BOM adviezen

Ga naar de commissie BOM adviezen over melanoom. 

Richtlijnen

Ga naar de richtlijn Melanoom in de FMS richtlijnen­database.

Ga naar de richtlijn Melanoom van VKGN - StOET.